HK1154513A1 - Modified kunitz domain polypeptides and their use for reducing ischemia or the onset of a systemic inflammatory response associated with a surgical procedure - Google Patents

Modified kunitz domain polypeptides and their use for reducing ischemia or the onset of a systemic inflammatory response associated with a surgical procedure

Info

Publication number
HK1154513A1
HK1154513A1 HK11108870.5A HK11108870A HK1154513A1 HK 1154513 A1 HK1154513 A1 HK 1154513A1 HK 11108870 A HK11108870 A HK 11108870A HK 1154513 A1 HK1154513 A1 HK 1154513A1
Authority
HK
Hong Kong
Prior art keywords
phe
cys
glu
ala
gly
Prior art date
Application number
HK11108870.5A
Other languages
English (en)
Chinese (zh)
Inventor
Robert Charles Ladner
Arthur C Ley
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp filed Critical Dyax Corp
Publication of HK1154513A1 publication Critical patent/HK1154513A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
HK11108870.5A 2002-06-07 2008-12-31 Modified kunitz domain polypeptides and their use for reducing ischemia or the onset of a systemic inflammatory response associated with a surgical procedure HK1154513A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38723902P 2002-06-07 2002-06-07
US40700302P 2002-08-28 2002-08-28

Publications (1)

Publication Number Publication Date
HK1154513A1 true HK1154513A1 (en) 2012-04-27

Family

ID=29739936

Family Applications (3)

Application Number Title Priority Date Filing Date
HK08114131.3A HK1119955A1 (en) 2002-06-07 2008-12-31 Modified kunitz domain polypeptide
HK11108085.6A HK1154211A1 (zh) 2002-06-07 2008-12-31 預防和減少失血和炎症反應
HK11108870.5A HK1154513A1 (en) 2002-06-07 2008-12-31 Modified kunitz domain polypeptides and their use for reducing ischemia or the onset of a systemic inflammatory response associated with a surgical procedure

Family Applications Before (2)

Application Number Title Priority Date Filing Date
HK08114131.3A HK1119955A1 (en) 2002-06-07 2008-12-31 Modified kunitz domain polypeptide
HK11108085.6A HK1154211A1 (zh) 2002-06-07 2008-12-31 預防和減少失血和炎症反應

Country Status (13)

Country Link
US (13) US7064107B2 (fr)
EP (4) EP2298278B1 (fr)
JP (3) JP2005534647A (fr)
AT (2) ATE477020T1 (fr)
AU (3) AU2003243394B2 (fr)
CA (1) CA2488558C (fr)
CY (1) CY1112228T1 (fr)
DE (1) DE60333758D1 (fr)
DK (4) DK1531791T3 (fr)
ES (4) ES2372978T3 (fr)
HK (3) HK1119955A1 (fr)
PT (4) PT1531791E (fr)
WO (1) WO2003103475A2 (fr)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
ES2229236T3 (es) 1994-01-11 2005-04-16 Dyax Corporation Inhibidores de la plasmina humana derivados de los dominios de kunitz.
US6801634B2 (en) 2000-07-31 2004-10-05 Harman International Industries, Inc. Loudspeaker coil suspension system
US20050222023A1 (en) * 2002-02-07 2005-10-06 Hans-Peter Hauser Albumin-fused kunitz domain peptides
US7153829B2 (en) * 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
ATE477020T1 (de) * 2002-06-07 2010-08-15 Dyax Corp Prevention und verringerung von ischemia
PT2386310T (pt) * 2002-08-28 2019-02-05 Dyax Corp Métodos para preservar órgãos e tecidos
US6989369B2 (en) * 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
CA2536873C (fr) * 2003-08-29 2019-09-10 Dyax Corp. Inhibiteurs de protease poly-pegylee
DE602004030264D1 (de) * 2003-09-12 2011-01-05 Z Medica Corp Teilweise hydriertes hämostatisches mittel
US20060177971A1 (en) * 2004-01-13 2006-08-10 Jsr Corporation Anisotropically conductive connector, production process thereof and application product thereof
US7235530B2 (en) * 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
DK1830924T3 (da) * 2004-12-23 2013-05-21 Csl Behring Gmbh Forebyggelse af thrombedannelse og/eller -stabilisering
US20060178609A1 (en) 2005-02-09 2006-08-10 Z-Medica, Llc Devices and methods for the delivery of molecular sieve materials for the formation of blood clots
WO2006088912A2 (fr) 2005-02-15 2006-08-24 Virginia Commonwealth University Technologies minerales pour une hemostase aigue et pour le traitement de lesions aigues et d'ulceres chroniques
US9829494B2 (en) 2005-12-01 2017-11-28 Adrenomed Ag Methods of treatment using ADM antibodies
JP2009529542A (ja) * 2006-03-10 2009-08-20 ダイアックス コーポレーション エカランチドに関する配合物
EP2374472B9 (fr) * 2006-03-16 2019-06-12 Dyax Corp. Compositions et procédé de traitement de troubles ophtalmiques
HUE039108T2 (hu) * 2006-03-16 2018-12-28 Dyax Corp Készítmények és eljárások szembetegségek kezelésére
US8938898B2 (en) * 2006-04-27 2015-01-27 Z-Medica, Llc Devices for the identification of medical products
US7604819B2 (en) 2006-05-26 2009-10-20 Z-Medica Corporation Clay-based hemostatic agents and devices for the delivery thereof
US8202532B2 (en) 2006-05-26 2012-06-19 Z-Medica Corporation Clay-based hemostatic agents and devices for the delivery thereof
US7968114B2 (en) 2006-05-26 2011-06-28 Z-Medica Corporation Clay-based hemostatic agents and devices for the delivery thereof
US20080085300A1 (en) * 2006-10-06 2008-04-10 Z-Medica Corporation Hemostatic compositions and method of manufacture
US9345457B2 (en) 2006-12-13 2016-05-24 Devicor Medical Products, Inc. Presentation of biopsy sample by biopsy device
WO2009026334A2 (fr) * 2007-08-21 2009-02-26 Genzyme Corporation Traitement par des inhibiteurs de la kallikréine
AU2008288772A1 (en) * 2007-08-23 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
WO2009032884A1 (fr) * 2007-09-05 2009-03-12 Z-Medica Corporation Cicatrisation de blessure avec des dispositifs hémostatiques à base de zéolite
AU2010203712A1 (en) 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
JP6037841B2 (ja) 2010-01-06 2016-12-07 ダイアックス コーポレーション 血漿カリクレイン結合タンパク質
EP2347778A1 (fr) 2010-01-25 2011-07-27 ECP Entwicklungsgesellschaft mbH Pompe à fluide dotée d'un rotor radial comprimable
US8858969B2 (en) 2010-09-22 2014-10-14 Z-Medica, Llc Hemostatic compositions, devices, and methods
AU2012204202A1 (en) 2011-01-06 2013-07-11 Dyax Corp. Plasma kallikrein binding proteins
CA2838984A1 (fr) 2011-06-10 2012-12-13 Isis Pharmaceuticals, Inc. Procedes pour moduler l'expression de la kallicreine (klkb1)
EP2726153B1 (fr) 2011-06-29 2018-03-28 Ionis Pharmaceuticals, Inc. Procédés de modulation de l'expression de kallicréine (klkb1)
SG11201402362VA (en) 2011-11-16 2014-06-27 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
DK2780717T3 (en) 2011-11-16 2017-02-13 Sphingotec Gmbh ADRENOMEDULLINASSAYS AND METHODS FOR DETERMINING MODERN ADRENOMEDULLIN
JP6321545B2 (ja) 2011-11-16 2018-05-09 アドレノメト アクチェンゲゼルシャフト 治療法における使用のための抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場
DK3553084T3 (da) 2011-11-16 2023-02-20 Adrenomed Ag Anti-adrenomedullin (adm)-antistof eller anti-adm-antistoffragment eller anti-adm-non-ig-scaffold til forebyggelse eller reduktion af organdysfunktion eller organsvigt hos en patient med en kronisk eller akut sygdom eller akut tilstand
LT2780371T (lt) 2011-11-16 2019-05-27 Adrenomed Ag Adrenomeduliną (adm) atpažįstantis antikūnas arba anti-adm antikūno fragmentas, arba anti-adm ne ig struktūros karkasas, skirti paciento, sergančio lėtine arba ūmia liga, skysčių pusiausvyros reguliavimui
EP2780370B1 (fr) 2011-11-16 2019-09-25 AdrenoMed AG Anticorps anti-adrénomédulline (adm) ou fragment d'anticorps anti-adm ou échafaudage non-ig anti-adm pour l'application thérapeutique en cas d'une maladie aiguë ou d'un état aigu d'un patient pour la stabilisation de la circulation
CN103308673B (zh) 2012-03-08 2017-05-31 思芬构技术有限公司 用于预测雌性对象中发生心血管事件的风险的方法
CN103308689B (zh) 2012-03-08 2017-04-12 思芬构技术有限公司 用于预测雌性对象中患上癌症的风险或诊断癌症的方法
CN103308670B (zh) 2012-03-08 2017-06-09 思芬构技术有限公司 用于预测对象患糖尿病和/或代谢综合征的风险的方法
KR102189877B1 (ko) 2012-06-22 2020-12-14 지-메디카 엘엘씨 지혈 장치
CA2886779C (fr) 2012-10-02 2022-11-01 Sphingotec Gmbh Methode permettant de diagnostiquer ou de surveiller la fonction renale ou de diagnostiquer une dysfonction renale
ES2879023T3 (es) 2013-01-08 2021-11-19 Sphingotec Gmbh Niveles en ayunas de la hormona de crecimiento como marcador predictivo de riesgo cardiovascular
SI2946206T1 (sl) 2013-01-20 2019-06-28 Dyax Corp. Ocenjevanje, testi in zdravljenje motenj, pri katerih posreduje PKA
ES2692408T3 (es) 2013-01-20 2018-12-03 Dyax Corp. Evaluación y tratamiento de trastornos mediados por bradiquinina
EP2976646B1 (fr) 2013-03-20 2020-08-19 sphingotec GmbH Adrénomédulline pour guider la thérapie du déclin de la pression sanguine
EP3715457A3 (fr) 2013-08-28 2020-12-16 Ionis Pharmaceuticals, Inc. Modulation de l'expression de la prékallikréine (pkk)
IL284969B (en) 2013-10-21 2022-07-01 Dyax Corp Diagnosis and treatment of autoimmune diseases
WO2015061183A1 (fr) 2013-10-21 2015-04-30 Dyax Corp. Dosages destinés à déterminer la présence de biomarqueurs du système kallikréine plasmatique
KR102424183B1 (ko) 2014-01-21 2022-07-26 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질 및 유전성 혈관부종을 치료하는 데 있어서의 이의 용도
US10428158B2 (en) 2014-03-27 2019-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
US10294477B2 (en) 2014-05-01 2019-05-21 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating PKK expression
EP3002589A1 (fr) 2014-10-01 2016-04-06 sphingotec GmbH Procédé de stratification d'un sujet femelle pour de l'hormonothérapie substitutive
IL305207A (en) 2015-03-30 2023-10-01 Takeda Pharmaceuticals Co Plasma kallikrein inhibitors and their uses to prevent the outbreak of hereditary angioedema
WO2016170023A1 (fr) 2015-04-24 2016-10-27 Sphingotec Gmbh Méthode permettant de prédire le risque d'incidence d'une maladie rénale chronique
KR102698737B1 (ko) 2015-10-19 2024-08-27 다케다 파머수티컬 컴패니 리미티드 절단된 고분자량 키니노겐의 검출을 위한 면역검정법
CN108602893A (zh) 2015-12-11 2018-09-28 戴埃克斯有限公司 血浆激肽释放酶抑制剂及其治疗遗传性血管性水肿发作的用途
EP4417218A2 (fr) 2016-04-21 2024-08-21 4TEEN4 Pharmaceuticals GmbH Procédés de détermination de dpp3 et procédés thérapeutiques
MA45493A (fr) 2016-06-27 2019-05-01 Aicuris Anti Infective Cures Gmbh Inhibiteurs d'entrée de hcmv.
SG11201900133WA (en) 2016-07-08 2019-02-27 Sphingotec Gmbh Adrenomedullin for assessing congestion in a subject with acute heart failure
AU2017325983B2 (en) 2016-09-16 2023-12-07 Takeda Pharmaceutical Company Limited Protein biomarkers for diseases associated with the contact activation system
EP3513188A1 (fr) 2016-09-16 2019-07-24 Dyax Corp. Biomarqueurs d'arn pour l'angioedème héréditaire
IL314752A (en) 2016-09-16 2024-10-01 Takeda Pharmaceuticals Co Metabolite biomarkers for diseases associated with the contact activation system
EP3309550A1 (fr) 2016-10-12 2018-04-18 sphingotec GmbH Procédé pour la détection de l'apolipoprotéine e4
EP3339324A1 (fr) 2016-12-22 2018-06-27 sphingotec GmbH Anticorps anti-adrénomedulline (adm) ou fragment d'anticorps anti-adm ou échafaudage anti-adm non-ig destiné à être utilisé dans l'intervention et la thérapie de congestion chez un patient ayantbesoin
CN110167962B (zh) 2016-12-16 2024-06-07 艾德里诺医药公司 用于干预和治疗需要的患者的充血的抗肾上腺髓质素(ADM)抗体或抗ADM抗体片段或抗ADM非Ig支架
JP7271442B2 (ja) 2017-05-30 2023-05-11 シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング 腎機能を診断またはモニターする方法、または腎機能障害を診断することを補助する方法
US20220227854A1 (en) 2017-09-25 2022-07-21 Adrenomed Ag Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness
BR112020005682A2 (pt) 2017-10-18 2020-10-20 Adrenomed Ag monitoração de terapia sob tratamento com um aglutinante de antiadrenomedulina (adm)
SG11202002391PA (en) 2017-10-24 2020-04-29 Sphingotec Gmbh Selenoprotein p for prediction of a first cardiovascular event
JP7424972B2 (ja) 2017-10-25 2024-01-30 ４ティーン４ ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング 特定のｄｐｐ３エピトープに指向され、そしてそれに結合するｄｐｐ３バインダー、ならびに酸化ストレスに関連する疾患／急性病態の予防または治療におけるその使用
EP3569614A1 (fr) 2018-05-18 2019-11-20 Julius-Maximilians-Universität Würzburg Composés et procédés pour l'immobilisation des inhibiteurs de myostatine sur la matrice extracellulaire par la transglutaminase
EP3586865A1 (fr) 2018-06-21 2020-01-01 Charité - Universitätsmedizin Berlin Liants d'anaphylatoxine de complément et leur utilisation dans le traitement d'un sujet présentant une plaie oculaire et/ou une fibrose
CN113056304A (zh) 2018-08-30 2021-06-29 戴埃克斯有限公司 用于治疗遗传性血管性水肿发作的血浆激肽释放酶抑制剂及其用途
CN113631926A (zh) 2018-12-20 2021-11-09 思芬构技术有限公司 心力衰竭中的硒蛋白p
EP3897686A2 (fr) 2018-12-21 2021-10-27 4TEEN4 Pharmaceuticals GmbH Guidage thérapeutique et/ou surveillance thérapeutique pour un traitement avec un agoniste du récepteur de l'angiotensine et/ou un précurseur de celui-ci
JP2022525164A (ja) 2019-03-14 2022-05-11 武田薬品工業株式会社 遺伝性血管性浮腫の発作を処置するための血漿カリクレイン阻害剤およびその使用
BR112022001417A2 (pt) 2019-08-15 2022-05-24 Sphingotec Gmbh Método para diagnóstico ou monitoramento de função renal ou diagnóstico de disfunção renal em pacientes pediátricos
RU2712629C1 (ru) * 2019-08-27 2020-01-30 Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Астраханский ГМУ Минздрава России) Способ прогнозирования сердечно-сосудистых осложнений у больных ишемической болезнью сердца в сочетании с постинфарктной аневризмой левого желудочка
CA3148275A1 (fr) 2019-08-30 2021-03-04 4TEEN4 Pharmaceuticals GmbH Orientation de therapie et/ou surveillance de therapie permettant le traitement d'un choc
AU2021209045A1 (en) 2020-01-13 2022-07-28 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack
EP3871689A1 (fr) 2020-02-26 2021-09-01 sphingotec GmbH Anticorps anti-adm se liant à l'extrémité n-terminale libre pour accélérer la transition de l'adm-gly vers la bio-adm chez les patients dont le rapport adm-gly/bio-adm est supérieur à un seuil et combinaison avec la vitamine c
CN115244401A (zh) 2020-02-27 2022-10-25 4Teen4制药有限公司 用于在休克患者中进行nt-adm抗体的治疗指导、监测和分层的dpp3
CN115244081A (zh) 2020-02-27 2022-10-25 艾德里诺医药公司 用于治疗休克患者的抗肾上腺髓质素(adm)结合剂
CN115244080A (zh) 2020-02-27 2022-10-25 艾德里诺医药公司 用于治疗或预防休克的抗肾上腺髓质素(ADM)抗体或抗ADM抗体片段或抗ADM非Ig支架
EP4121763A1 (fr) 2020-03-16 2023-01-25 4TEEN4 Pharmaceuticals GmbH Dpp3 chez des patients infectés par un coronavirus
EP3922993A1 (fr) 2020-06-12 2021-12-15 4TEEN4 Pharmaceuticals GmbH Dpp3 chez des patients infectés par le coronavirus
MX2022011581A (es) 2020-03-16 2022-10-18 Adrenomed Ag Proadrenomedulina o fragmento de la misma en pacientes infectados con coronavirus y tratamientos con aglutinante contra la adrenomedulina.
US20230174674A1 (en) 2020-04-04 2023-06-08 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating acute respiratory distress syndrome
EP4023218A1 (fr) 2020-12-02 2022-07-06 S-Form Pharma Thérapie combinée pour les patients souffrant d'une dyspnée aiguë et/ou persistante
CN117529664A (zh) 2021-06-18 2024-02-06 思芬构技术有限公司 用于预测脓毒症和脓毒性休克的方法
WO2023275099A1 (fr) 2021-06-29 2023-01-05 Berysol Gmbh Biomarqueur composite d'identification de déficience en sélénium dans un fluide corporel
WO2024003617A2 (fr) 2022-06-30 2024-01-04 Takeda Pharmaceutical Company Limited Biomarqueurs protéiques pour traitement au lanadelumab
WO2024023369A1 (fr) 2022-07-29 2024-02-01 Adrenomed Ag Anticorps anti-adrénomédulline (adm) ou fragment d'anticorps anti-adm ou échafaudage non-ig anti-adm destiné à être utilisé en thérapie ou prévention du choc
WO2024023368A1 (fr) 2022-07-29 2024-02-01 4TEEN4 Pharmaceuticals GmbH Prédiction d'augmentation de dpp3 chez un patient souffrant d'un choc septique
WO2024126793A1 (fr) 2022-12-15 2024-06-20 4TEEN4 Pharmaceuticals GmbH Inhibiteur de dpp3 pour l'amélioration de la fonction pulmonaire chez des patients gravement malades
WO2024194276A1 (fr) 2023-03-17 2024-09-26 Pam Theragnostics Gmbh Procédés de détermination de peptidylglycine monooxygénase alpha-amidante et son utilisation à des fins diagnostiques
WO2024200862A1 (fr) 2023-03-29 2024-10-03 4TEEN4 Pharmaceuticals GmbH Inhibiteur dpp3 pour la protection myocardique et la prévention d'une lésion myocardique chez des patients gravement malades avec déclin de la pression artérielle

Family Cites Families (211)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT275583B (de) 1964-03-04 1969-10-27 Plasser Bahnbaumasch Franz Profilfreie Maschine zum Reinigen des Eisenbahnbettungsschotters
BR6915369D0 (pt) 1969-02-27 1973-03-13 Bayer Ag Emprego de inibidores biologicos de proteases para conservacao de orgaos tecidos e alimentos
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (fr) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Procede de fixation d'une proteine sur un substrat
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE2619246A1 (de) 1976-04-30 1977-11-10 Bayer Ag Desamino-derivate des kallikrein- trypsin-inhibitors, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
DE2654124A1 (de) 1976-11-29 1978-06-01 Bayer Ag Derivate des trypsin-kallikrein-inhibitors aus rinderorganen (bpti) mit proteasenhemmwirkung und antiphlogistischer wirkung, ihre herstellung und ihre verwendung als arzneimittel
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (fr) 1977-02-17 1981-01-20 Hideo Hirohara Traduction non-disponible
EP0003248A1 (fr) * 1977-11-09 1979-08-08 Animark Products Limited Composition et méthode pour le blanchiment des cheveux ou de fibres kératiniques
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
AT359653B (de) 1979-02-15 1980-11-25 Immuno Ag Verfahren zur herstellung eines gewebekleb- stoffes
US4299537A (en) * 1979-06-19 1981-11-10 Evans Frederick C Interlinked variable-pitch blades for windmills and turbines
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
AU560584B2 (en) 1983-07-28 1987-04-09 Bayer Aktiengesellschaft Homologues of aprotinin
US4657893A (en) 1984-05-09 1987-04-14 Syntex (U.S.A.) Inc. 4H-3,1-benzoxazin-4-ones and related compounds and use as enzyme inhibitors
US4845242A (en) 1987-04-28 1989-07-04 Georgia Tech Research Corporation Isocoumarins with basic substituents as serine proteases inhibitors, anticoagulants and anti-inflammatory agents
US4609725A (en) 1984-10-09 1986-09-02 Merck & Co., Inc. Cardiac atrial peptides
US4931385A (en) 1985-06-24 1990-06-05 Hygeia Sciences, Incorporated Enzyme immunoassays and immunologic reagents
US5444156A (en) * 1985-07-12 1995-08-22 Temple University-Of The Commonwealth System Of Higher Education Monoclonal antibodies to human plasma prekallikrein
JPH0623113B2 (ja) 1986-01-31 1994-03-30 浩 前田 癌性胸・腹水貯留抑制剤
EP0255011A3 (fr) 1986-07-29 1988-11-23 Miles Inc. Gène humain pour l'inhibiteur d'inter-alpha-trypsine
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
ATE169673T1 (de) 1986-11-17 1998-08-15 Scios Inc Rekombiniertes alzheimer amyloid-protein
US5187153A (en) 1986-11-17 1993-02-16 Scios Nova Inc. Methods of treatment using Alzheimer's amyloid polypeptide derivatives
EP0285123A3 (fr) 1987-04-03 1989-02-01 Stabra AG Méthode de mutagénèse complète d'acides nucléiques
US4966852A (en) 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
IL87172A (en) 1987-07-23 1994-12-29 Univ Washington A method of inhibiting the isolation of a purer tissue factor
US5106833A (en) 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
GB2208511A (en) * 1987-08-07 1989-04-05 Bayer Ag Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology
DK225488D0 (da) 1988-04-26 1988-04-26 Novo Industri As Polypeptid
IL87171A (en) 1987-11-23 1995-08-31 Monsanto Co ANDC of human tissue factor inhibitor
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0768377A1 (fr) 1988-09-02 1997-04-16 Protein Engineering Corporation Production et sélection de protéines de liaison diversifiées de recombinaison
US5663143A (en) 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US7078383B2 (en) 1988-09-02 2006-07-18 Dyax Corp. ITI-D1 Kunitz domain mutants as HNE inhibitors
US5372933A (en) * 1988-10-03 1994-12-13 The Scripps Research Institute Polypeptides that mimic receptor-induced binding sites, and methods of using same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0401508B1 (fr) 1989-05-13 1994-11-23 Bayer Ag Inhibiteurs de protéinase, leur procédé de préparation ainsi que compositions pharmaceutiques les contenant
DK408089D0 (da) 1989-08-18 1989-08-18 Novo Nordisk As Proteiner
US5378614A (en) 1989-08-18 1995-01-03 Novo Nordisk A/S Vector and method for making tissue factor pathway inhibitor (TFPI) analogues in yeast
US5278285A (en) 1990-02-01 1994-01-11 Bayer Aktiengesellschaft Variant of Kunitz-type inhibitor derived from the α3-chain of human type VI collagen produced by recombinant DNA technology
US5583107A (en) 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US5278144A (en) 1990-09-04 1994-01-11 Cor Therapeutics, Inc. Antithrombosis agents
IL99585A0 (en) 1990-10-01 1992-08-18 Novo Nordisk As Aprotinin analogues,their production and pharmaceutical compositions containing them
EP0486001A1 (fr) 1990-11-13 1992-05-20 Mochida Pharmaceutical Co., Ltd. Fragments recombinants de l'inhibiteur urinaire de la trypsine et composition pharmaceutique
US20030223977A1 (en) 1991-03-01 2003-12-04 Ley Arthur Charles Kunitz domain mutants as cathepsin G inhibitors
US5166133A (en) 1991-04-17 1992-11-24 Cetus Corporation Method for inhibing adhesion of white blood cells to endothelial cells
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
WO1993009233A2 (fr) 1991-10-31 1993-05-13 The Salk Institute Biotechnology/Industrial Associates Inc. Domaine des inhibiteurs de proteine de precurseur amyloïde et traitement de divers etats pathologiques
IL104327A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
IL104314A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Human kunitz-type protease inhibitor and variants thereof,their production and pharmaceutical compositions containing them
IL104324A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
IL104326A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
IL104325A (en) 1992-01-07 2000-10-31 Novo Nordisk As Variants of human kunitz-type protease inhibitor domain II of tissue factor pathway inhibitor (TFPI) pharmaceutical compositions containing them a DNA construct encoding them their expression vectors a cell containing said DNA constructs and methods for the production of all the above
US5212091A (en) 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
US6063764A (en) 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
US5747449A (en) * 1992-07-13 1998-05-05 Corvas International, Inc. Bovine pancreatic trypsin inhibitor derived inhibitors of factor XA
EP0740702A1 (fr) 1992-12-02 1996-11-06 Zymogenetics, Inc. Nouvel homologue de precurseur de proteine amyloide humaine et nouveaux inhibiteurs de type kunitz
US5436153A (en) * 1992-12-02 1995-07-25 Sprecher; Cindy A. Human amyloid protein precursor homolog and Kunitz-type inhibitor
US5426224A (en) 1993-03-18 1995-06-20 The University Of North Carolina At Chapel Hill Mammalian DNA topoisomerase II inhibitor and method
WO1995007986A1 (fr) * 1993-09-14 1995-03-23 Genentech, Inc. Compositions pharmaceutiques contenant l'ecotine et des homologues de celle-ci
US5455338A (en) 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5759548A (en) 1993-11-30 1998-06-02 Lxr Biotechnology Inc. Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
ATE275583T1 (de) 1994-01-11 2004-09-15 Dyax Corp KALLIKREINHEMMENDE ßKUNITZ-DOMÄNEß-PROTEINE UND DERIVATEN DAVON
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
ES2229236T3 (es) 1994-01-11 2005-04-16 Dyax Corporation Inhibidores de la plasmina humana derivados de los dominios de kunitz.
US5795954A (en) * 1994-03-04 1998-08-18 Genentech, Inc. Factor VIIa inhibitors from Kunitz domain proteins
EP0763055B1 (fr) 1994-06-02 1999-11-03 Merrell Pharmaceuticals Inc. Inhibiteurs d'elastase au perfluoroalkyle cetone et procedes de production associes
CA2196296C (fr) 1994-08-05 2004-04-06 Michael A. Innis Production d'inhibiteurs des voies du facteur tissulaire de la coagulation
US5589359A (en) 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
US5648331A (en) 1994-08-26 1997-07-15 G.D. Searle & Co. Method of inhibiting tissue ischemia and reperfusion injury
EP0788546B9 (fr) * 1994-10-18 2007-06-13 Dendreon Corporation Proteines anticoagulantes et inhibiteurs de la serine-protease extraits de nematodes
US6159938A (en) * 1994-11-21 2000-12-12 Cortech, Inc. Serine protease inhibitors comprising α-keto heterocycles
EP1609477B1 (fr) * 1994-12-12 2011-11-09 Omeros Corporation Solution d'irrigation et utilisation de celle-ci pour inhiber périopérativement la douleur, l'inflammation et/ou les spasmes au niveau d'une structure vasculaire
US5914316A (en) 1994-12-16 1999-06-22 Washington University Method of inhibiting intimal hyperplasia
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
WO1996028427A1 (fr) * 1995-03-10 1996-09-19 Berlex Laboratories, Inc. Derives de benzamidine et utilisation de ces derives en tant qu'anticoagulants
US5695760A (en) 1995-04-24 1997-12-09 Boehringer Inglehiem Pharmaceuticals, Inc. Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation
US5804376A (en) 1995-05-02 1998-09-08 Incyte Pharmaceuticals, Inc. Pancreas-derived serpin
CA2220497A1 (fr) 1995-05-08 1996-11-14 Scios, Inc. Peptides inhibiteurs de proteases de type kunitz
ZA963619B (en) 1995-05-08 1996-11-22 Scios Inc Protease inhibitor peptides
US5780265A (en) * 1995-06-05 1998-07-14 Genentech, Inc. Kunitz type plasma kallikrein inhibitors
US5786328A (en) * 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
US6242414B1 (en) 1995-06-07 2001-06-05 Chiron Corporation Regulation of cytokine synthesis and release
US6126933A (en) 1995-06-27 2000-10-03 Genetics Institute Methods of treating inflammatory bowel diseases by administering IL-11
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
JPH0959838A (ja) 1995-08-24 1997-03-04 Kuraray Co Ltd 紡績糸
JPH11512439A (ja) 1995-09-14 1999-10-26 エルエックスアール バイオテクノロジー インコーポレイテッド リン脂質の混合物を含む抗アポトーシス活性を有する組成物
WO1997010847A1 (fr) 1995-09-21 1997-03-27 University Of Utah Research Foundation Ciblage de conjugues de poly(ethylene glycol) et d'anticorps contre l'acide glutamique decarboxylase sur des cellules insulaires
US5824870A (en) 1995-11-06 1998-10-20 Baszczynski; Chris Commercial production of aprotinin in plants
US5736364A (en) * 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
BR9509985A (pt) * 1995-12-12 1998-11-03 Omeros Med Sys Inc Solução para irrigação e método para inibição de dor inflamação e esparmo
HU226419B1 (en) 1996-03-11 2008-12-29 Aerovance Human bikunin
US6013763A (en) * 1996-06-04 2000-01-11 Genentech, Inc. Peptide variants of protein A
JP3657700B2 (ja) * 1996-06-18 2005-06-08 新日本石油化学株式会社 カサ高性不織布の製造方法
US5869637A (en) 1996-07-22 1999-02-09 Incyte Pharmaceuticals, Inc. Human Kallikrein
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US6255455B1 (en) 1996-10-11 2001-07-03 The Trustees Of The University Of Pennsylvania Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
US6258351B1 (en) 1996-11-06 2001-07-10 Shearwater Corporation Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels
CA2279345A1 (fr) 1997-01-31 1998-08-06 Human Genome Sciences, Inc. Inhibiteur des voies de la thromboplastine tissulaire 3
US5786238A (en) * 1997-02-13 1998-07-28 Generyal Dynamics Information Systems, Inc. Laminated multilayer substrates
US5962300A (en) 1997-03-26 1999-10-05 Incyte Pharmaceuticals, Inc. Human kallikrein
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
JP2003525845A (ja) 1997-10-28 2003-09-02 ヴィヴァス・インコーポレイテッド 勃起機能不全の処置のためのホスホジエステラーゼインヒビターの局所投与
JP3786832B2 (ja) 1998-01-07 2006-06-14 デビオ ルシェルシュ ファルマシュティーク ソシエテ アノニム 分解性のヘテロ二官能性ポリ（エチレングリコール）アクリレート及びそれから誘導されるゲル及び複合体
JP4078032B2 (ja) 1998-03-12 2008-04-23 ネクター セラピューティックス エイエル，コーポレイション 近位の反応性基を持つポリ（エチレングリコール）誘導体
AU2855499A (en) 1998-03-24 1999-10-18 Nof Corporation Oxirane derivatives and process for producing the same
US6017723A (en) 1998-03-27 2000-01-25 Long Island Jewish Medical Center Method for isolating inhibitors of protease activity
US6001596A (en) 1998-05-07 1999-12-14 Incyte Pharmaceuticals, Inc. Growth-associated protease inhibitor heavy chain precursor
US6087473A (en) * 1999-05-26 2000-07-11 Zymogenetics, Inc. Kunitz domain polypeptide and materials and methods for making it
AU4229599A (en) * 1998-06-03 1999-12-20 Scios Inc. Protease inhibitor peptides
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
ATE498409T1 (de) 1998-08-06 2011-03-15 Mountain View Pharmaceuticals Peg-uricase konjugate und verwendung davon
JP2002524076A (ja) 1998-09-03 2002-08-06 ザイモジェネティクス，インコーポレイティド ＫｕｎｉｔｚドメインポリペプチドＺＫＵＮ６
US7067144B2 (en) 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
JP2002531089A (ja) 1998-11-30 2002-09-24 イーライ・リリー・アンド・カンパニー 赤血球産生性化合物
JP2002534959A (ja) 1998-12-08 2002-10-22 バイオベーション リミテッド 免疫原性タンパク質の改変方法
US20030012969A1 (en) 1999-04-06 2003-01-16 Clark Bert Thomas Soluble membrane strengthened paper products
CN1550235A (zh) 1999-04-29 2004-12-01 ŵ��Ų�ڿ˹�˾ 结合肝素的拮抗剂在缓激肽释放的抑制中的应用
US6605316B1 (en) 1999-07-31 2003-08-12 The Regents Of The University Of California Structures and fabrication techniques for solid state electrochemical devices
US6180607B1 (en) 1999-08-05 2001-01-30 Christopher Davies Protein having proteinase inhibitor activity
US6984720B1 (en) 1999-08-24 2006-01-10 Medarex, Inc. Human CTLA-4 antibodies
JP2003513681A (ja) 1999-11-12 2003-04-15 マキシゲン・ホールディングス・リミテッド インターフェロンガンマ・コンジュゲート
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
US6544760B2 (en) 1999-12-22 2003-04-08 Zymogenetics, Inc. Kunitz domain polypeptide Zkun11
ATE424431T2 (de) 1999-12-22 2009-03-15 Nektar Therapeutics Al Corp Verfahren zur herstellung von 1- benzotriazolcarbonatestern von wasserlöslichen polymeren
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
US20020102703A1 (en) 1999-12-29 2002-08-01 Sheppard Paul O. Kunitz domain polypeptide zkun10
GB9930882D0 (en) * 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
WO2001068707A1 (fr) 2000-03-13 2001-09-20 Eli Lilly And Company Homologue inhibiteur d'activateur de facteur de croissance des hepatocytes humains
CA2405557C (fr) 2000-04-12 2013-09-24 Human Genome Sciences, Inc. Proteines hybrides d'albumine
CN1331213A (zh) 2000-06-30 2002-01-16 上海博德基因开发有限公司 一种新的多肽——人大蛋白10.01和编码这种多肽的多核苷酸
DE10034357C1 (de) 2000-07-14 2001-12-13 Elotherm Gmbh Verfahren und Vorrichtung zum Härten von Flächen an Bauteilen
JP2004509617A (ja) 2000-09-08 2004-04-02 シェーリング　コーポレイション 哺乳動物遺伝子；関連試薬および方法
CN1287856C (zh) 2000-10-31 2006-12-06 德比奥药物股份有限公司 Epi－hne蛋白质干粉
US20030113726A1 (en) 2000-12-04 2003-06-19 Zenta Tsuchihashi Human single nucleotide polymorphisms
TW593427B (en) 2000-12-18 2004-06-21 Nektar Therapeutics Al Corp Synthesis of high molecular weight non-peptidic polymer derivatives
WO2002092147A2 (fr) 2001-05-11 2002-11-21 Aradigm Corporation Optimisation des proprietes moleculaires et formulation de proteines delivrees par inhalation
NZ529572A (en) 2001-05-21 2006-02-24 Nektar Therapeutics Pulmonary administration of chemically modified insulin
US20040152633A1 (en) 2001-05-31 2004-08-05 Jorgensen Marianne Ulrich Kunitz-type sequences and polypeptides
US20030096733A1 (en) 2001-07-10 2003-05-22 Omnio Ab Novel drug targets for arthritis
CN100366965C (zh) 2001-07-10 2008-02-06 日本电产三协株式会社 阀驱动设备
NZ534492A (en) 2002-02-07 2009-10-30 Novozymes Delta Ltd Albumin-fused kunitz domain peptides
US20050222023A1 (en) 2002-02-07 2005-10-06 Hans-Peter Hauser Albumin-fused kunitz domain peptides
AU2003231865A1 (en) 2002-05-31 2003-12-19 Genzyme Corporation Alpha acyloxyacetamides for kallikrein and urokinase inhibition
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
ATE477020T1 (de) * 2002-06-07 2010-08-15 Dyax Corp Prevention und verringerung von ischemia
EP1526872A1 (fr) 2002-07-24 2005-05-04 F. Hoffmann-La Roche Ag Additifs d'acides de polyalkyleneglycol
CN100357317C (zh) 2002-07-24 2007-12-26 弗·哈夫曼-拉罗切有限公司 聚乙二醇化的t20多肽
PT2386310T (pt) * 2002-08-28 2019-02-05 Dyax Corp Métodos para preservar órgãos e tecidos
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
AU2003303635B2 (en) 2002-12-26 2009-07-23 Mountain View Pharmaceuticals, Inc. Polymer conjugates of interferon-beta with enhanced biological potency
DE602004031589D1 (de) 2003-01-07 2011-04-14 Dyax Corp Kunitz-domäne-bibliothek
ATE404176T1 (de) 2003-01-08 2008-08-15 Novartis Vaccines & Diagnostic Stabilisierte lyophilisierte zubereitungen mit gewebefaktor-inhibitor (tfpi) oder varianten des gewebefaktor-inhibitors
EP2174663A1 (fr) 2003-01-08 2010-04-14 Novartis Vaccines and Diagnostics, Inc. Compositions aqueuses stabilisées renfermant un inhibiteur de la voie du facteur tissulaire (TEPI) ou des variantes du TEPI
DE10301300B4 (de) 2003-01-15 2009-07-16 Curacyte Chemistry Gmbh Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein
US6989369B2 (en) * 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
US20060205671A1 (en) 2003-07-02 2006-09-14 Jakob Vinten-Johansen Compositions and methods for use of a protease inhibitor and adenosine for preventing organ ischemia and reperfusion injury
EP1660537A2 (fr) 2003-08-14 2006-05-31 Dyax Corp. Ligands de l'endotheliase-2
WO2005021556A2 (fr) 2003-08-29 2005-03-10 Dyax Corp. Inhibiteurs de protease modifies
CA2536873C (fr) 2003-08-29 2019-09-10 Dyax Corp. Inhibiteurs de protease poly-pegylee
WO2005027753A1 (fr) 2003-09-19 2005-03-31 St. Jude Medical, Inc. Appareil et procede pour collecter et fixer un tissu
US7268109B2 (en) 2003-10-02 2007-09-11 Elan Pharmaceuticals, Inc. Method for reducing pain
US20060228331A1 (en) 2003-10-10 2006-10-12 Novo Nordisk A/S IL-21 Derivatives and variants
WO2005041631A2 (fr) 2003-10-21 2005-05-12 Dyax Corp. Ligands de l'endotheliase-1
EP1713929A2 (fr) 2004-02-03 2006-10-25 Bayer HealthCare AG Agents diagnostiques et therapeutiques pour des maladies associees a la kallikreine plasmatique (klkb1)
JP4775259B2 (ja) 2004-03-31 2011-09-21 味の素株式会社 アニリン誘導体
JP2008515774A (ja) 2004-08-03 2008-05-15 ダイアックス コーポレイション ｈＫ１結合タンパク質
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
CA2587775A1 (fr) 2004-11-22 2006-06-01 Dyax Corp. Therapies inhibitrices de la plasmine
ITMI20042442A1 (it) 2004-12-21 2005-03-21 Aliveris S R L Paste alimentari con migliorate caratteristiche di digeribilita'
DK1830924T3 (da) 2004-12-23 2013-05-21 Csl Behring Gmbh Forebyggelse af thrombedannelse og/eller -stabilisering
WO2006089005A2 (fr) 2005-02-17 2006-08-24 Bristol-Myers Squibb Company Nouvelle combinaison d'inhibiteurs selectifs du facteur viia et/ou du facteur xia et d'inhibiteurs selectifs de kallicreine plasmatique
WO2006091459A2 (fr) 2005-02-24 2006-08-31 Joslin Diabetes Center, Inc. Compositions et methodes permettant de traiter la permeabilite vasculaire
WO2006117565A2 (fr) 2005-05-04 2006-11-09 Zealand Pharma A/S Analogues du glp-2 (glucagon-like-peptide-2)
CA2561626C (fr) 2005-09-30 2013-11-26 9141-0720 Quebec Inc. Dispositif de fermeture motorise avec systeme de commande electronique
US20070079096A1 (en) 2005-09-30 2007-04-05 Chih-Wei Chen Data storage unit access authorization table automatic rebuilding method and system
SI1981519T1 (en) 2005-12-29 2018-05-31 Dyax Corp. INHIBITION PROTEAZE
US7276480B1 (en) * 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
JP2009529542A (ja) * 2006-03-10 2009-08-20 ダイアックス コーポレーション エカランチドに関する配合物
HUE039108T2 (hu) 2006-03-16 2018-12-28 Dyax Corp Készítmények és eljárások szembetegségek kezelésére
US20080031426A1 (en) 2006-06-27 2008-02-07 Weeks Walter L Audio, video, and navigational law enforcement system and method
EP1873344A1 (fr) 2006-06-30 2008-01-02 Sika Technology AG Agglutination étanchée par silicone
EP2051707B1 (fr) 2006-07-31 2013-07-17 Activesite Pharmaceuticals, Inc. Inhibiteurs de kallicréine plasmatique
US20080299050A1 (en) 2006-10-05 2008-12-04 Drugtech Corporation Topical therapies for oral mucositis and other conditions
WO2009026334A2 (fr) 2007-08-21 2009-02-26 Genzyme Corporation Traitement par des inhibiteurs de la kallikréine
AU2008288772A1 (en) 2007-08-23 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
AU2009214590A1 (en) 2008-02-13 2009-08-20 Dyax Corp. Improved methods for producing specific binding pairs
DE102008027574A1 (de) 2008-06-10 2009-12-17 Merck Patent Gmbh Neue Pyrrolidinderivate als MetAP-2 Inhibitoren
DE102008033095A1 (de) 2008-07-15 2010-01-28 Uhde Gmbh Vorrichtung zur Schlackeabführung aus einem Kohlevergasungsreaktor
AU2010203712A1 (en) 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
JP6037841B2 (ja) 2010-01-06 2016-12-07 ダイアックス コーポレーション 血漿カリクレイン結合タンパク質
AU2012204202A1 (en) 2011-01-06 2013-07-11 Dyax Corp. Plasma kallikrein binding proteins
WO2012142308A1 (fr) 2011-04-13 2012-10-18 Activesite Pharmaceuticals, Inc. Promédicaments d'inhibiteurs de la kallicréine plasmatique
SI2946206T1 (sl) 2013-01-20 2019-06-28 Dyax Corp. Ocenjevanje, testi in zdravljenje motenj, pri katerih posreduje PKA
US10428158B2 (en) 2014-03-27 2019-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema

Also Published As

Publication number Publication date
CA2488558A1 (fr) 2003-12-18
EP1531791A4 (fr) 2008-05-21
ES2559927T3 (es) 2016-02-16
JP2013049698A (ja) 2013-03-14
CA2488558C (fr) 2013-08-20
US20080200646A1 (en) 2008-08-21
EP2298278A1 (fr) 2011-03-23
US20190247477A1 (en) 2019-08-15
AU2008202377B2 (en) 2011-05-12
WO2003103475A2 (fr) 2003-12-18
US20040038893A1 (en) 2004-02-26
US11344610B2 (en) 2022-05-31
EP1531791A2 (fr) 2005-05-25
JP2010155842A (ja) 2010-07-15
CY1112228T1 (el) 2015-12-09
ATE477020T1 (de) 2010-08-15
US20060194727A1 (en) 2006-08-31
US20090082267A1 (en) 2009-03-26
US8124586B2 (en) 2012-02-28
JP5249251B2 (ja) 2013-07-31
HK1119955A1 (en) 2009-03-20
EP2311432A1 (fr) 2011-04-20
ATE528014T1 (de) 2011-10-15
DE60333758D1 (de) 2010-09-23
US20160361395A1 (en) 2016-12-15
US20080064637A1 (en) 2008-03-13
PT1531791E (pt) 2010-12-16
ES2348230T3 (es) 2010-12-01
US20080076712A1 (en) 2008-03-27
US20080152656A1 (en) 2008-06-26
EP2298278B1 (fr) 2015-11-11
EP2311432B1 (fr) 2014-12-24
PT1941867E (pt) 2012-02-16
US8710007B2 (en) 2014-04-29
AU2008202377A1 (en) 2008-06-19
US20080260752A1 (en) 2008-10-23
AU2011201811A1 (en) 2011-05-19
PT2298278E (pt) 2016-02-25
WO2003103475A3 (fr) 2005-03-10
ES2372978T3 (es) 2012-01-30
HK1154211A1 (zh) 2012-04-13
ES2528254T3 (es) 2015-02-05
US20110086801A1 (en) 2011-04-14
DK1941867T3 (da) 2012-01-02
US7811991B2 (en) 2010-10-12
US7851442B2 (en) 2010-12-14
DK1531791T3 (da) 2010-11-01
AU2003243394B2 (en) 2008-06-12
JP2005534647A (ja) 2005-11-17
AU2003243394A1 (en) 2003-12-22
US20080131426A1 (en) 2008-06-05
EP1531791B1 (fr) 2010-08-11
EP1941867B1 (fr) 2011-10-12
EP1941867A1 (fr) 2008-07-09
US10245307B2 (en) 2019-04-02
DK2298278T3 (en) 2016-02-01
US7064107B2 (en) 2006-06-20
US9480733B2 (en) 2016-11-01
PT2311432E (pt) 2015-02-09
US20140349940A1 (en) 2014-11-27
DK2311432T3 (en) 2015-02-02

Similar Documents

Publication Publication Date Title
HK1154513A1 (en) Modified kunitz domain polypeptides and their use for reducing ischemia or the onset of a systemic inflammatory response associated with a surgical procedure
NO942553L (no) Ny humanproteaseinhibitor av Kunitz-type og varianter derav
WO2002002597A3 (fr) Polypeptides glycosyles a extension peptidique
DE69942035D1 (de) Menschliches parathyroidhormon, modifikationen, herstellung und verwendung
DE60329201D1 (de) Substituierte wt1-peptide
DE69128664D1 (de) CNP-Gen und Vorläuferprotein aus Schwein
WO2001005810A3 (fr) DERIVES PEPTIDIQUES CYCLIQUES SERVANT D'INHIBITEURS DE L'INTEGRINE αVβ¿6?
WO2004014937A3 (fr) Peptides dérivés de la thrombine
NZ334714A (en) Liver proteins as agents against autoimmune diseases
HUP9702500A2 (hu) Elhízás elleni proteinek
CY1115911T1 (el) Τροποποιημενα πολυπεπτιδια περιοχης kunitz και η χρηση τους στην μειωση της ισχαιμιας ή της εκκινησης μιας συστημικης φλεγμονωδους ανταποκρισης που σχετιζεται με μια χειρουργικη επεμβαση
ES2171157T3 (es) Gen recombinante codificante para una proteina con actividad endoquitinasa.
ATE388965T1 (de) Menschliche antithrombin-varianten
FR2787454B1 (fr) Inhibiteur de la topoisomerase ii
IL115825A0 (en) Therapeutic protein
WO1999057262A3 (fr) Peptide se liant aux ions de metal
NZ332946A (en) Modified forms of interleukin-5 molecules capable of antagonising of IL-5
DE60326726D1 (de) Peptide mit affinität für ein phospholipid und deren verwendung
TH56074B (th) ตัวยับยั้ง (อัลฟาv เบตา6) อินทีกริน

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20230602